Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs
24 Octobre 2022 - 1:30PM
Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or
the “Company”), a biopharmaceutical company committed to developing
innovative therapeutic solutions for underserved mental health
conditions, announced today that it has appointed Edward Smith as
the Company’s Chief Financial Officer and Aviva Asnis-Alibozek as
Vice President, Medical Affairs, effective immediately. Both Mr.
Smith and Dr. Asnis-Alibozek will report to Greg Mayes, Reunion’s
President and CEO.
“As Reunion progresses its Phase 1 clinical
trial with our innovative lead asset RE-104, we continue to add
highly skilled, results-driven healthcare industry veterans to our
executive bench to solidify the Company’s position as a leader in
the development of novel therapies for the treatment of mental
health disorders,” said Mr. Mayes. “I look forward to working
closely with Ed and Aviva to take Reunion to the next level and
continue advancing our mission to bring novel treatments to market
in an effort to address today’s mental health epidemic.”
Edward Smith is an industry veteran with more
than 20 years of financial management experience and has served as
CFO of several publicly traded, clinical-stage biotechnology
companies where has successfully raised over $600 million from
institutional investors. Prior to joining Reunion, Mr. Smith was
CFO and took public LAVA Therapeutics N.V., Marinus
Pharmaceuticals, Inc. and PolyMedix, Inc. and prior to that, he was
executive director of finance at InKine Pharmaceutical Company,
Inc., where he assisted with the acquisition of that company by
Salix Pharmaceuticals, Inc. Earlier in his career, he held various
positions of increasing responsibility in public accounting, most
recently in the audit practice at Deloitte & Touche, LLP. Mr.
Smith is currently a member of the board of directors at Benitec
Biopharma, Inc. He holds a B.S. in business administration from the
University of Hartford and was licensed as a Certified Public
Accountant in Pennsylvania.
Dr. Aviva Asnis-Alibozek is a Board-certified
physician assistant and graduate of the Yale School of Medicine.
She obtained a specialized Master of Physician Assistant Studies
degree in oncology and was appointed a Distinguished Fellow of the
American Academy of Physician Assistants. Prior to joining Reunion,
Dr. Asnis-Alibozek served as a medical affairs and clinical and
commercial development consultant at Viva Bio Pharma Services,
LLC., where she partnered with agency, industry, academic and
community oncology professionals to advance the care of patients
with cancer and inflammatory diseases. Prior to that, Dr.
Asnis-Alibozek served as Executive Vice President of Global Medical
Affairs at TRM Oncology, a division of Aptitude Health, where she
managed the ongoing delivery of the company’s medical and
scientific strategy executed by the clinical content, publications
and business development teams. Earlier in her career, she held
various industry positions at AstraZeneca Pharmaceuticals,
Pharmacia Corporation, IBA Molecular, Inc. and Research to
Practice. Dr. Asnis-Alibozek earned her Doctor of Medical Science
degree in the advanced professional practice of administrative
medicine from the University of Lynchburg.
“As Reunion prepares to begin its Phase 2 study
in postpartum depression next year, the Company will significantly
benefit from Ed and Aviva’s decades of collective expertise in the
industry,” added Mr. Mayes. “Reunion continues to attract the
highest-caliber talent in its mission to revolutionize mental
health treatments, beginning with postpartum depression and later
extending to several other indications with significant unmet
medical needs.”
Edward Smith succeeds Donna Wong who has
resigned as Chief Financial Officer. Ms. Wong will continue as the
Corporate Secretary of the Corporation for the time being to ensure
an orderly transition. The Company wishes to sincerely thank Ms.
Wong for her contributions to the Company.
About Reunion Neuroscience Inc.
Reunion (formerly, Field Trip Health Ltd.) is committed to
developing innovative therapeutic solutions for mental health
conditions. The Company’s lead asset, RE-104 (previously known as
FT-104), is a proprietary, novel serotonergic psychedelic compound
being developed as a potential fast-acting and durable
antidepressant for patients suffering from post-partum and
treatment resistant depression. Reunion is also developing the
FT-200 series, which includes compounds with potential for more
selective serotonin receptor activity with reduced psychoactivity
for potential use in more chronic treatment paradigms and
indications.
Learn more at
https://investors.reunionneuro.com, and
https://www.reunionneuro.com.
Follow us on LinkedIn, Twitter and
Instagram.
To be added to the Reunion Neuroscience email
list, please email Reunion@kcsa.com with “REUN” in the subject
line.
Cautionary Note Regarding
Forward-Looking Information This release
includes forward-looking information (within the meaning of
Canadian securities laws and within the meaning of the United
States Private Securities Litigation Reform Act of 1995) regarding
the Company and its business. Often but not always, forward-looking
information can be identified by the use of words such as "expect",
"intends", "anticipated", "believes" or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results "may", "could", "would" or
"will" be taken, occur or be achieved. Such statements are based on
the current expectations and views of future events of the
management of the Company and are based on assumptions and subject
to risks and uncertainties. Although the management of believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and the
Company does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise. Additional information
relating to Field Trip, including its Annual Information Form, can
be located on the SEDAR website at www.sedar.com and on the EDGAR
section of the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Media Contact:Shana
Marino KCSA Strategic Communications(347)
487-6189reunion@kcsa.com
Investor Contacts:Phil Carlson /
Sophia BashfordKCSA Strategic Communications(646) 573-0776 / (929)
246-7307reunion@kcsa.com
Reunion Neuroscience (TSX:REUN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Reunion Neuroscience (TSX:REUN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024